123 related articles for article (PubMed ID: 18569844)
21. [Edifying affair of hydroxycarbamid].
Nau JY
Rev Med Suisse; 2008 Apr; 4(152):940. PubMed ID: 18578439
[No Abstract] [Full Text] [Related]
22. Effect of hydroxyurea on immature reticulocyte fraction in sickle cell anemia.
Bagdasaryan R; Glasser L; Quillen K; Chaves F; Xu D
Lab Hematol; 2007; 13(3):93-7. PubMed ID: 17984040
[TBL] [Abstract][Full Text] [Related]
23. Altered levels of cytokines and inflammatory mediators in plasma and leukocytes of sickle cell anemia patients and effects of hydroxyurea therapy.
Lanaro C; Franco-Penteado CF; Albuqueque DM; Saad ST; Conran N; Costa FF
J Leukoc Biol; 2009 Feb; 85(2):235-42. PubMed ID: 19004988
[TBL] [Abstract][Full Text] [Related]
24. Periodic erythroexchange is an effective strategy for high risk paediatric patients with sickle-cell disease.
Masera N; Tavecchia L; Pozzi L; Riva F; Vimercati C; Calabria M; Ronzoni S; Masera G; Perseghin P
Transfus Apher Sci; 2007 Dec; 37(3):241-7. PubMed ID: 18042436
[TBL] [Abstract][Full Text] [Related]
25. Principles and indications of chronic transfusion therapy for children with sickle cell disease.
Ware R
Clin Adv Hematol Oncol; 2007 Sep; 5(9):686-8. PubMed ID: 17982409
[No Abstract] [Full Text] [Related]
26. [Sickle cell disease in the Democratic Republic of the Congo: what are the barriers to treatment using hydroxyurea?].
Mukinayi BM; Cibeyibeyi GK; Tumba GD; Gulbis B
Pan Afr Med J; 2021; 38():41. PubMed ID: 33854670
[TBL] [Abstract][Full Text] [Related]
27. Analysis of purity profiles of generic lisinopril tablets marketed in Croatia.
Benković G; Sokolić M; Cudina B; Zulj RT; Tomić S
Coll Antropol; 2013 Jun; 37(2):601-6. PubMed ID: 23941010
[TBL] [Abstract][Full Text] [Related]
28. Effective use of hydroxyurea for sickle cell anemia in low-resource countries.
Power-Hays A; Ware RE
Curr Opin Hematol; 2020 May; 27(3):172-180. PubMed ID: 32205588
[TBL] [Abstract][Full Text] [Related]
29. Quality of generic ophthalmic drugs.
Novack GD
Ocul Surf; 2013 Jan; 11(1):54-6. PubMed ID: 23321360
[No Abstract] [Full Text] [Related]
30. Quality Testing of Difficult-to-Make Prescription Pharmaceutical Products Marketed in the US.
Fisher AC; Viehmann A; Ashtiani M; Friedman RL; Buhse L; Kopcha M; Woodcock J
JAMA Netw Open; 2020 Aug; 3(8):e2013920. PubMed ID: 32833019
[TBL] [Abstract][Full Text] [Related]
31. Structural and pharmacological profile of generic enoxaparins used in Brazil.
Lima MA; de Farias EH; Gray A; Sadeghi N; Gesteira TF; Cavalheiro RP; Hoppensteadt D; Fareed J; Sassaki GL; Nader HB
Clin Appl Thromb Hemost; 2012 Jul; 18(4):379-86. PubMed ID: 22395574
[TBL] [Abstract][Full Text] [Related]
32. Hydroxyurea for SCA in Africa: no malaria harm.
Odame I
Blood; 2017 Dec; 130(24):2575-2576. PubMed ID: 29242203
[No Abstract] [Full Text] [Related]
33. Antisickling properties of divanilloylquinic acids isolated from Fagara zanthoxyloides Lam. (Rutaceae).
Ouattara B; Jansen O; Angenot L; Guissou IP; Frédérich M; Fondu P; Tits M
Phytomedicine; 2009 Mar; 16(2-3):125-9. PubMed ID: 19110407
[TBL] [Abstract][Full Text] [Related]
34. MRI abnormalities in infants with sickle cell anemia-indication for preemptive therapy?
Ozsahin H
Pediatr Blood Cancer; 2008 Nov; 51(5):573-4. PubMed ID: 18623220
[No Abstract] [Full Text] [Related]
35. Ten-year review of hospital admissions among children with sickle cell disease in Kuwait.
Akar NA; Adekile A
Med Princ Pract; 2008; 17(5):404-8. PubMed ID: 18685282
[TBL] [Abstract][Full Text] [Related]
36. Hydroxyurea therapy lowers circulating DNA levels in sickle cell anemia.
Ulug P; Vasavda N; Kumar R; Keir L; Awogbade M; Cunningham J; Rees DC; Menzel S; Thein SL
Am J Hematol; 2008 Sep; 83(9):714-6. PubMed ID: 18615556
[TBL] [Abstract][Full Text] [Related]
37. Physiochemical properties of generic formulations of tacrolimus in Mexico.
Petan JA; Undre N; First MR; Saito K; Ohara T; Iwabe O; Mimura H; Suzuki M; Kitamura S
Transplant Proc; 2008 Jun; 40(5):1439-42. PubMed ID: 18589125
[TBL] [Abstract][Full Text] [Related]
38. A comparative neutron activation analysis study of common generic manipulated and reference medicines commercialized in Brazil.
Leal AS; Menezes MA; Rodrigues RR; Andonie O; Vermaercke P; Sneyers L
Appl Radiat Isot; 2008 Oct; 66(10):1307-12. PubMed ID: 18455924
[TBL] [Abstract][Full Text] [Related]
39. Comparing generic and innovator drugs: a review of 12 years of bioequivalence data from the United States Food and Drug Administration.
Davit BM; Nwakama PE; Buehler GJ; Conner DP; Haidar SH; Patel DT; Yang Y; Yu LX; Woodcock J
Ann Pharmacother; 2009 Oct; 43(10):1583-97. PubMed ID: 19776300
[TBL] [Abstract][Full Text] [Related]
40. The presence of alpha-thalassaemia trait blunts the response to hydroxycarbamide in patients with sickle cell disease.
Vasavda N; Badiger S; Rees D; Height S; Howard J; Thein SL
Br J Haematol; 2008 Nov; 143(4):589-92. PubMed ID: 18764867
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
